BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

iCo Therapeutics Inc. Selected as Canada's Top 10(TM) Competition Winner


10/13/2010 11:59:32 AM

VANCOUVER, BRITISH COLUMBIA--(Marketwire - October 13, 2010) - iCo Therapeutics Inc. (TSX VENTURE: ICO) is pleased to announce that the company has been selected as one of Canada's Top 10™ Competition winners. Top 10™ winners are chosen by an independent expert panel of Canadian and U.S. venture capitalists. The panel can be viewed at http://www.topcanadiancompanies.ca/jury/lifesciences.html.

Competition winners may participate in a series of investment forums in select cities across the U.S. Developed together with key sponsors, partners and the Canadian consulates in each city, the forums expose the Top 10™ companies to an exclusive opportunity to present to top tier U.S. and Canadian venture capitalists, licensing executives and potential strategic partners in a series of invitation only events.

"I continue to be impressed by the quality of companies that I see coming out of Canada," says Bernhardt Zeisig, Partner, Cycle Ventures LLC. "Because of programs like this, I get to review companies that I would normally not see. This competition is an effective way to put companies in front of investors like us."

About Canada's Top 10™ Competition

The vision for the Canada's Top 10™ is to be Canada's premier investment oriented competition by selecting the best potential investments in Canada for investors and providing high value added services to companies to increase their chances of success, both as they source investment and as they grow and compete in the global environment. Since its inception, competition alumni have secured more than $600M in venture capital financing. http://www.topcanadiancompanies.com/.

About iCo Therapeutics

iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. iCo has exclusive worldwide rights to three products: iCo-007, moving into Phase II for the treatment of DME, iCo-008; a product with Phase II clinical history to be developed for severe ocular allergies and age-related macular degeneration; and iCo-009, an oral formulation of Amphotericin B for sight and life-threatening diseases. iCo-009 also represents a new drug delivery technology with the potential to reprofile other parenteral administered drugs to the oral route of administration. iCo was recently awarded a Gold Leaf Award as the Early Stage Company of the Year from BIOTECanada and trades on the TSX Venture Exchange under the symbol "ICO". For more information, visit the Company website at: www.icotherapeutics.com

Forward Looking Statements

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo Therapeutics' current beliefs as well as assumptions made by and information currently available to iCo Therapeutics and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo Therapeutics in its public securities filings; actual events may differ materially from current expectations. iCo Therapeutics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

No regulatory authority has approved or disapproved the content of this release. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.


Contacts:
iCo Therapeutics Inc. - Business Development
Dr. John Clement
CTDO
604-602-9414 x 222

iCo Therapeutics Inc. - Finance
Mr. John Meekison
CFO
604-602-9414 x 224

iCo Therapeutics Inc. - Investor/Media Contact
Frederica Jensen
604-602-9414 x 226
www.icotherapeutics.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES